What could happen to the economy when antibiotics stop working

Jeremy Veillard

Manager, Health Policy and Regulations, World Bank Group

A crisis hiding in plain sight, antimicrobial resistance (AMR) is threatening health, development and poverty reduction. It demands urgent global action.


When antimicrobials fail, countries face higher healthcare costs, worsened health outcomes, reduced labour productivity and disrupted supply chains. The stakes are highest for low-income countries.

Unchecked AMR threatens lives and economies

Poor antibiotic stewardship and rising AMR could cause 38.5 million deaths between 2025 and 2050. Over the same period, cumulative global GDP losses are estimated at USD $1.1 trillion and could reach USD $5.2 trillion by 2050.1 If left unchecked, AMR could push 28.3 million more people into extreme poverty by 2050, including 26 million in lower and middle-income countries.2

Without action, the treatment of resistant bacterial infections alone will impose a global economic burden of USD $412 billion in healthcare costs and USD $443 billion in lost productivity annually up to 2035.3 Not acting with urgency on AMR will also compromise progress on Universal Health Coverage in Low- and Middle-Income countries, including the World Bank Group objective of achieving access to quality, affordable health services to 1.5 billion people by 2030.4 

Investments in health systems, agriculture, water and economic reform projects, deploying USD $2.6 billion in financing across 30 countries

The market paradox of AMR

AMR is not only a public health crisis. It is a growing burden on the private sector. Businesses face rising healthcare costs, reduced workforce productivity, disruptions to food systems and supply chains and gradual erosion of medical procedures that underpin modern healthcare. While businesses are absorbing these mounting costs, the commercial incentives needed to drive investments in AMR prevention, including biosecurity measures, diagnostics and vaccines, remain critically limited.

A collective investment imperative to tackle AMR

Finance ministries are uniquely positioned to drive the systemic change that AMR demands. By allocating resources, aligning incentives, and ensuring accountability across sectors, they hold the levers needed to embed AMR into broader development and economic planning. Countries must prioritise long-term domestic investment across health systems, agriculture, animal health and the environment, treating AMR not as a narrow public health concern but as a cross-sectoral whole-of-economy solution. Public officials must also look beyond government budgets, engaging the private sector to drive more responsible antimicrobial use.

The World Bank Group incorporates AMR considerations into investments in health systems, agriculture, water and economic reform projects, deploying USD $2.6 billion in financing across 30 countries and mobilising approximately USD $1 billion in private livestock and aquaculture investments. Working alongside governments and private sector clients, our approach is designed to generate meaningful, measurable progress in reducing AMR, without placing the burden on governments to compete for scarce, earmarked funding. 

[1] McDonnell A et al. – Forecasting the Fallout from AMR: Economic Impacts of Antimicrobial Resistance in Humans – A report from the EcoAMR series. Paris (France) and Washington, DC (United States of America): World Organisation for Animal Health and World Bank, 2024.
[2] Jonas, O. B. et al. Drug-resistant Infections: A Threat to Our Economic Future, Vol. 2: Final Report. HNP/Agriculture Global Antimicrobial Resistance Initiative (World Bank Group, Washington, DC, 2024).
[3] Global Leader’s Group on AMR Report. TOWARDS SPECIFIC COMMITMENTS AND ACTION IN THE RESPONSE TO ANTIMICROBIAL RESISTANCE Recommendations for consideration by UN Member States in the outcome document of the High-level Meeting on AMR in September 2024.
[4] WBG Publication: Reaching 1.5 Billion People with Quality, Affordable Health Services; Target Implementation Plan, July 8, 2026

More from AMR & Infectious Diseases